ONCOLOGY LETTERS 15: 4813-4820, 2018

Oncological safety of nipple-sparing mastectomy in young patients with breast cancer compared with conventional mastectomy

JIAPENG HUANG1*, QINGGUO MO1*, YAQIANG ZHUANG2, QINGHONG QIN1, ZHEN HUANG1, JUNYANG MO3, QIXING TAN1, BIN LIAN1, YIMING CAO2, SHUTING QIN3 and CHANGYUAN WEI1

1Second Department of Breast Surgery, Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi 530021; 2Second Department of Breast and Thyroid Surgery; 3First Department of Breast and Thyroid Surgery, Liuzhou People’s Hospital, Liuzhou, Guangxi 545006, P.R. China

Received July 23, 2017; Accepted December 12, 2017

DOI: 10.3892/ol.2018.7913

Abstract. Although nipple-sparing mastectomy (NSM) is being used more frequently, the oncological safety of NSM remains unclear, particularly in young patients (<35 years). The aim of the present study was to compare the rates of local recurrence (LR), disease-free survival (DFS) and overall survival (OS) in young patients with breast cancer who had undergone NSM or conventional mastectomy (CM). The clinicopathological data of young patients with stage 0-IIB breast cancer who had undergone NSM (163 cases) or CM (194 cases) between 2007 and 2016 were retrospectively analyzed. The log-rank test was used to analyze the differences in the LR, DFS and OS rates between the two groups and multivariate analysis was used to analyze the patient prognostic factors for DFS. The median follow-up time was 49 months. Patients who had undergone CM were more likely to exhibit stage II disease (68.4 vs. 58.3%; P=0.015) and positive lymph nodes (45.9 vs. 33.1%; P=0.014). In the NSM group, LR occurred in 7 (4.3%) cases, systemic recurrence in 15 (9.2%) cases and mortality in 9 (5.5%) cases. In the CM group, LR occurred in 6 (3.1%) cases, systemic recurrence in 27 (13.9%) cases and mortality in 15 (7.7%) cases. There were no statistical differences in the LR, DFS and OS rates between the two groups (P>0.05). Following adjustment for clinical stage, the LR and DFS rates between the two groups exhibited no significant differences. Analysis of the prognostic factors demonstrated that clinical stage, lymph node status, estrogen and progesterone receptor status and human epidermal growth factor receptor 2 status were associated with DFS (P<0.05). NSM is safe for young patients with early-stage breast cancer and provides patients with an improved cosmetic outcome. Furthermore, nipple-areola complex preservation does not increase the risk of recurrence.

Introduction

In the 1800s, Halsted first practiced and standardized radical mastectomy (RM) (1). Subsequently, surgery for breast cancer has significantly improved with regards to oncological safety and cosmetic outcome. In 1965, Madden (2) first introduced modified RM (MRM), which has since been frequently performed clinically. RM and MRM are grouped with conventional mastectomy (CM), and the local recurrence (LR) rate following CM was ~10% 10 years after surgery (3-5).

In 1991, Toth and Lappert (6) first described skin-sparing mastectomy (SSM), which involves removing the mammary glands, including the nipple-areola complex (NAC), while preserving the native skin envelope and the inframammary fold. The oncological safety (local disease control) of SSM has been demonstrated to be equivalent to that of MRM (7,8). Nipple-sparing mastectomy (NSM) is similar to SSM, but does not involve removal of the NAC (9). In 1984, Hinton et al (10) first reported that the LR and survival rates following NSM were equivalent to those following MRM; however, this conclusion was not accepted by prominent surgeons at the time due to the fact that the NAC may harbor occult tumor cells, thereby increasing the risk of LR (11,12). Previous studies have reported NAC involvement in 5-12% of cases (13,14). Over time, an increasing number of studies have reported that NSM may provide oncological safety compared with CM for carefully selected patients (15-19).

The young age of certain patients has been revealed to be associated with a poor prognosis and an increased risk of LR in breast cancer (20-22), an effect which may be explained, in part, by diagnosis at a later stage and a higher proportion of unfavorable tumor characteristics (23-25). Although young age was previously a contraindication for breast-conserving surgery (BCS), later studies have reported that young
patients who had undergone BCS may exhibit oncological safety compared with those who had undergone CM (26). Banema-Joppe et al (27) reported that the 10-year overall survival (OS) rate of patients following BCS was not impaired, compared with traditional mastectomy in young patients with early-stage breast cancer. Furthermore, the oncological safety of NSM in young patients with breast cancer has rarely been reported and remains poorly understood.

In the present study, LR, disease-free survival (DFS) and OS rates were investigated in young patients with early-stage breast cancer who had undergone NSM or CM.

Materials and methods

Data collection. The information of young patients with stage 0-IIB breast cancer who had undergone NSM (163 cases) or CM (194 cases) at Guangxi Medical University Affiliated Tumor Hospital (Nanning, China; 103 NSM cases and 126 CM cases) and Liuzhou People's Hospital (Liuzhou, China; 60 NSM cases and 68 CM cases), between January 2007 and June 2016, was collected. Patient clinicopathological data were collected, including age at diagnosis, tumor size, nodal status, Tumor-Node-Metastasis (TNM) stage (28), histological grade, estrogen receptor (ER) and progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER-2) expression, surgical procedures, complications and adjuvant treatment regimens. Follow-up data included LR time, systemic recurrence time and patient mortality.

Inclusion and exclusion criteria. The inclusion criteria for the present study were as follows: i) Patients who had undergone NSM or CM; ii) patients aged <35 years; iii) female patients; and iv) patients with synchronous bilateral invasive breast cancer or metastasis; ii) patients who had not received adjuvant treatment; iii) patients without available pathological data; iv) patients with synchronous bilateral invasive breast cancer or metachronous contralateral breast cancer; and v) patients without follow-up records. A total of 357 patients were included in the present study.

Surgery. Patients who had been found to be contraindicated with BCS by preoperative imaging, including magnetic resonance imaging, ultrasonography and mammography, and those who had explicitly rejected BCS, were eligible for NSM. Patients with possible tumor involvement in the NAC or surrounding skin, according to preoperative imaging, were not eligible for NSM. Based on the results of fine needle biopsies and clinical staging, CM was performed with or without a sentinel lymph node biopsy. Axillary lymph node dissection was routinely performed when metastasis to the sentinel lymph node had occurred. NSM removed the entire mammary gland parenchyma, including the skin overlying superficial tumors, when possible. Patients with a tumor-to-NAC distance <2 cm, nipple discharge or Paget's disease were not eligible for NSM. When performing NSM, in order to confirm that there was no tumor invasion to the NAC borders, frozen sections of the retroareolar tissue were routinely acquired for intraoperative histological diagnosis. The puncture point of the core biopsy was as far from the NAC and as close to the lump as possible. NSM was followed by immediate breast reconstruction with a permanent implant, latissimus dorsi myocutaneous flap (LD), extended LD (ELD), transverse rectus abdominis myocutaneous flap (TRAM) and deep inferior epigastric artery perforator flap (DIEP), which was performed by the same team in a single operative procedure. The reconstructive procedure was selected depending on the anatomical conditions and personal preferences of patients.

Adjuvant therapy. Adjuvant systemic treatment and radiation therapy were administered according to the National Comprehensive Cancer Network guidelines (29) and based on the postoperative pathological examinations. Adjuvant therapy included chemotherapy, endocrine therapy, radiotherapy and targeted therapy. Patients were normatively treated according to the most recent guidelines at the time of treatment.

Statistical analysis. The patient clinicopathological features were compared between the NSM and CM groups using the χ² (when the theoretical frequency was >1) or Fisher's exact tests (when the theoretical frequency was <1). The present study was not a randomized controlled trial and statistical differences in certain clinicopathological features, including the clinical TNM stage, of a number of patients were observed between the 2 groups. Therefore, Kaplan-Meier survival analysis, followed by the log-rank test, was used to compare the LR, DFS and OS rates between the two groups; and the clinical TNM stage-stratified log-rank test was also used to compare the LR and DFS rates. The Cox proportional hazards model was used to evaluate the prognostic factors of DFS. All statistical analyses were performed using SPSS version 22.0 (IBM Corp., Armonk, NY, USA). P<0.05 was considered to indicate a statistically significant difference.

Cosmetic assessment. The postoperative cosmetic outcome of the patients who had undergone NSM, followed by immediate breast reconstruction, was evaluated by a panel comprising three surgeons and patients, and was stratified into 5 grades (excellent, good, acceptable, poor or very poor). Evaluation was based on 4 criteria, including symmetry of size and shape, symmetry of NAC and inframammary fold, the visibility of scarring and skin color match. Each criterion was evaluated with 0 to 5 points. The total score 17 to 20 was categorized as excellent, 13 to 16 as good, 9 to 12 as acceptable, 5 to 8 as poor and 0 to 4 as very poor.

Ethical approval and informed consent. All procedures in the present study involving human participants were performed in accordance with the ethical standards of Guangxi Medical University Affiliated Tumor Hospital research committee (approval no. 14-06) and with the 1964 Declaration of Helsinki and its later amendments (30). The present study was approved by the Review Board of Guangxi Medical University Affiliated Tumor Hospital and Liuzhou People's Hospital. The study used only unidentifiable patient information and therefore, no written informed consent was required.
Results

Patient characteristics. A total of 357 patients were selected for the present study; of which, 163 patients (45.7%) had undergone NSM and 194 (54.3%) had undergone CM. The patient clinicopathological features are summarized in Table I. Patients who had undergone NSM exhibited a smaller tumor size, a lower proportion of lymph node metastasis and a lower proportion of stage II disease, compared with the CM group. There were no statistical differences in age, histological grade, ER and PR status and HER-2 status between the NSM and CM groups.

Surgery. All patients from the NSM group had undergone breast reconstruction, of which 148 patients (90.8%) had undergone immediate breast reconstruction and 15 patients (9.2%) had undergone delayed breast reconstruction. The reconstruction method included permanent implant (32 cases, 19.6%), LD (51 cases, 31.2%), ELD (59 cases, 36.2%), TRAM (18 cases, 11.0%) and DIEP (3 cases, 1.8%). Only 4 patients in the CM group had undergone delayed breast reconstruction with ELD or a tissue expander followed by a permanent implant. None of the patients in the CM group had undergone immediate breast reconstruction.

Complications. Nipple necrosis occurred in 4 patients (2.5%) who had undergone breast reconstruction with permanent implants, ELD and TRAM. Partial necrosis of breast skin or the myocutaneous flap was observed in 18 patients (11.0%) who had undergone breast reconstruction with permanent implants and TRAM. Complete necrosis of the myocutaneous flap was observed in 1 patient (0.6%) who had undergone breast reconstruction with DIEP. No flap necrosis was observed in the patients that had undergone breast reconstruction with LD or ELD. There were no patients with a hematoma requiring surgical intervention or an infection requiring removal of the implant.

Oncological outcomes. All patients were followed up for a period of 4-118 months, with a median follow-up time of 49 months. The median follow-up time in the NSM and CM groups were 39 months (range, 4-112 months) and 53 months (range, 4-118 months), respectively. In the NSM group, 22 patients (13.5%) experienced recurrence, of which 6 (27.3%) exhibited LR only, 15 (68.2%) exhibited systemic recurrence only and 1 (4.5%) exhibited LR and systemic recurrence. In the CM group, 33 patients (17.0%) experienced recurrence, of which 3 (9.1%) exhibited LR only, 27 (81.8%) exhibited systemic recurrence only and 3 (9.1%) exhibited LR and systemic recurrence.

There were no significant differences in the 5-year LR rate of the NSM and CM groups (4.3 vs. 3.1%; P=0.228; Fig. 1) or in the 5-year DFS rate of the two groups (86.5 vs. 83.0%; P=0.780; Fig. 2). The 5-year OS rates were similar for the two groups (94.5 vs. 92.3%; P=0.868; Fig. 3). Following adjustment for the clinical TNM stage, there were no statistically significant differences in the LR and DFS rates between the two groups (Figs. 4 and 5). In multivariate analysis (Table II), the significant risk factors for DFS following NSM or CM were positive lymph nodes, higher clinical TNM stage, negative ER/PR expression and positive HER-2 expression. The surgical procedure was not a significant risk factor for DFS (HR=1.041; 95% confidence interval=0.585-1.851; P=0.892).

| Characteristic | NSM group | CM group | P-value |
|----------------|-----------|----------|---------|
| Age, years     |           |          |         |
| <30            | 29        | 23       | 0.113   |
| 30-34          | 134       | 171      |         |
| T stage        |           |          | 0.047*  |
| T0             | 3         | 5        |         |
| T1             | 70        | 58       |         |
| T2             | 90        | 129      |         |
| T3             | 0         | 2        |         |
| Nodal status   |           |          | 0.014*  |
| +              | 54        | 89       |         |
| -              | 109       | 105      |         |
| Clinical TNM stage |    |          | 0.015*  |
| 0              | 3         | 5        |         |
| I              | 59        | 44       |         |
| II             | 58        | 68       |         |
| III            | 43        | 77       |         |
| Histological grade |      |          | 0.357   |
| I              | 35        | 31       |         |
| II             | 70        | 84       |         |
| III            | 58        | 79       |         |
| ER status      |           |          | 0.104   |
| +              | 111       | 116      |         |
| -              | 52        | 78       |         |
| PR status      |           |          | 0.314   |
| +              | 101       | 110      |         |
| -              | 62        | 84       |         |
| HER-2 status   |           |          | 0.148   |
| +              | 69        | 97       |         |
| -              | 78        | 73       |         |
| Unknown        | 16        | 24       | 12.4    |

*P<0.05. NSM, nipple-sparing mastectomy; CM, conventional mastectomy; T, tumor; TNM, tumor-node-metastasis; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2.

Table I. Comparison of clinical characteristics between the NSM group (n=163) and the CM group (n=194).

Treatment of LR with NSM. In the NSM group, 7 patients presented with LR. Of these cases, NAC, skin and incision scar recurrences were observed in 2 (1.2%), 4 (2.5%) and 1 case(s) (0.6%), respectively. The local recurrent lesions of the 6 patients with LR only were excised completely. All margins were negative and none of the patients required total...
mammary glands and NAC while sparing the skin envelope and the native inframammary fold (6). It has been demonstrated to be a safe procedure that provides good cosmetic results with excellent local tumor control rate (7,8,31). NSM is similar to SSM but it also preserves the NAC. Due to its preservation of the NAC, NSM has been considered to have potentially higher LR risks (11). NSM has been used for breast tumors with peripheral locations and even advanced disease (32).

Numerous previous prospective and retrospective studies, comprising patients with varying sample sizes, inclusion criteria and follow-up durations, have reported an LR rate of 0-24% following NSM (12,16-18,32-34). Although Benediktsson and Perbeck (33) reported a highest LR rate of 24% among these studies, the NAC recurrence rate was 4%. While a study undertaken by Adam et al (16) reported no LR in a group comprising 67 patients after 36 months. Shimo et al (34) determined an LR rate of 5.8% after 46.8 months (range, 6-158 months) for 425 patients who had undergone NSM and the cumulative LR rate at the NAC was 2.3%. Orzalesi et al (35) evaluated the oncological safety of NSM in a large sample size (1,006 cases), and reported an LR rate of 2.9% and a NAC recurrence rate of 0.7%. A meta-analysis of 73 studies (12,358 cases) between 1970 and 2015 assessed the incidence of LR following NSM (19). The mean follow-up time was 38 months (range, 7.4-156 months) and the overall LR rate was 2.38%. In recent years, studies have indicated that NSM was safe for oncology and led to similar LR and OS rates compared with those of patients treated with CM (18,34). These results were similar to those of the present study. In the present study, LR was observed in 7 patients (4.3%) in the NSM group, including 2 NAC recurrences (1.2%), and no significant difference was
observed in the 5-year LR rate between the NSM and CM groups (4.3 vs. 3.1%; P=0.228).

A number of previous studies have specialized in the oncological safety of young patients who have undergone NSM. In previous studies, the tumors observed in young patients have frequently exhibited a high histological grade, ER/PR negative status, HER-2 positive status, multifocal or multi-center presentation, high proliferation and lymphovascular invasion (23-25,36-39). The presence of these characteristics in young patients with breast cancer has generally been associated with a poorer prognosis (20,21). Fredholm et al (22) conducted a population-based study comprising 22,017 female patients with breast cancer and revealed that young age was a risk factor for loco-regional recurrence. In the present study, it was determined that young age did not increase the oncological risk for the female patients with early-stage breast cancer who had undergone NSM. There were no significant statistical differences in the 5-year LR, DFS and OS rates between the NSM and CM groups (Figs. 1-3).

In the present study, patients who had undergone CM exhibited a larger tumor size, a higher proportion of positive lymph nodes and a higher proportion of stage II disease, compared with those who had undergone NSM. There may have been a selection bias towards patients and the patients with early-stage cancer may have been offered NSM more frequently. Patients with a larger tumor size and positive lymph nodes exhibited a higher clinical TNM stage more frequently. In order to reduce the selection bias, analysis was adjusted for clinical TNM stage. It was determined that there were no significant statistical differences in the LR and DFS rates between the two groups when adjusted for clinical TNM stage (Figs. 4 and 5).

Benediktsson and Perbeck reported that LR was dependent on the lymph node status and clinical TNM stage (33). Petit et al (40) determined that the number of positive lymph nodes, histological type and Ki-67 index were significant predictive factors of LR based on multivariate analysis. Due to the limited number of LR cases, the prognostic factors of LR based on multivariate analysis could not be evaluated. However, it was revealed that the significant risk factors for DFS following NSM or CM were positive lymph nodes, negative ER/PR expression and positive HER-2 expression.

In addition to oncological safety, complication rates and cosmetic outcome are two other concerns associated with...
NSM. Due to the removal of the tissue beneath the NAC, NSM may cause an increased incidence of NAC necrosis. Headon et al (19) analyzed 73 studies in their meta-analysis and determined a nipple necrosis rate of 5.8% for 12,358 NSM procedures. In the present study, nipple necrosis occurred in 4 patients (2.5%), less than the result reported...
by Headon et al (19). Arteriosclerosis rarely occurs in young female patients and the majority of patients in the present study were non-smokers, which may be a reason for the low nipple necrosis rate observed. Furthermore, avoiding the use of high frequency electrotomes when removing the tissue beneath the NAC (41) and maintaining the thickness of the areola flap under the premise of oncological safety are also important for reducing nipple areola necrosis (42). One advantage of the NSM procedure, the cosmetic outcome, has been recognized by the majority of experts (43,44). Yueh et al (44) reported that the NSM procedure provided patients with a superior cosmetic outcome and psychological satisfaction. The majority of the patients that had undergone NSM followed by breast reconstruction in the present study obtained a satisfactory cosmetic appearance. The overall rates of ‘excellent’ and ‘good’ grades averaged 75.2%. A positive body image is particularly important for these young female patients with breast cancer. Physical defects in young women can lead to poorer mental health, lower self-esteem and sexual dysfunction, thereby significantly affecting their quality of life (45).

There were certain limitations associated with the present study. To begin with, the present study was retrospective and only comprised a small number of patients (357 cases), thereby resulting in unavoidable bias. In particular, the tendency to perform NSM on patients with early-stage cancer led to a selection bias. Secondly, the median follow-up time of the present study was 49 months (39 months for the NSM group and 53 months for the CM group), which was relatively short, compared with the long natural course of breast cancer. The present study only included patients <35 years of age. A longer follow-up is required to demonstrate the natural course of breast cancer in these young patients. Furthermore, the clinical TNM stages of patients in the present study were between stage 0 and IIIB, but these patients exhibited a relatively high proportion of recurrence and mortality. A considerable proportion of HER-2 positive patients may not have received Herceptin® therapy due to financial reasons, which posed a notable social problem.

In summary, compared with CM, NSM did not increase the risk of local and systemic recurrence in young patients with early-stage breast cancer in the present study. The NSM procedure achieved oncological safety and superior cosmetic outcomes for the young females with breast cancer. Therefore, NSM may become one of the standard procedures for the young females with breast cancer in these young patients. Furthermore, the clinical TNM stages of patients in the present study were between stage 0 and IIIB, but these patients exhibited a relatively high proportion of recurrence and mortality. A considerable proportion of HER-2 positive patients may not have received Herceptin® therapy due to financial reasons, which posed a notable social problem.

There were certain limitations associated with the present study. To begin with, the present study was retrospective and only comprised a small number of patients (357 cases), thereby resulting in unavoidable bias. In particular, the tendency to perform NSM on patients with early-stage cancer led to a selection bias. Secondly, the median follow-up time of the present study was 49 months (39 months for the NSM group and 53 months for the CM group), which was relatively short, compared with the long natural course of breast cancer. The present study only included patients <35 years of age. A longer follow-up is required to demonstrate the natural course of breast cancer in these young patients. Furthermore, the clinical TNM stages of patients in the present study were between stage 0 and IIIB, but these patients exhibited a relatively high proportion of recurrence and mortality. A considerable proportion of HER-2 positive patients may not have received Herceptin® therapy due to financial reasons, which posed a notable social problem.

In summary, compared with CM, NSM did not increase the risk of local and systemic recurrence in young patients with early-stage breast cancer in the present study. The NSM procedure achieved oncological safety and superior cosmetic outcomes for the young females with breast cancer. Therefore, NSM may become one of the standard procedures for the young patients with early-stage breast cancer when breast reconstruction is performed.

Acknowledgements

The authors would like to thank the colleagues at the Medical Records Room of Guangxi Medical University Affiliated Tumor Hospital and Liuzhou People’s Hospital for extracting the necessary information from the database and the technicians at the Department of Pathology at Guangxi Medical University Affiliated Tumor Hospital and Liuzhou People’s Hospital for providing assistance in dealing with archived samples. The authors also would like to thank the Statistics Teaching and Research Department of Guangxi Medical University for providing advice regarding statistical methods. The present study was supported by the National Natural Science Foundation of China (grant no. 81360396) and the Science and Technology Research Fund of Guangxi Zhuang Autonomous Region Science and Technology Department (grant no. 13550053-12).

Competing interests

The authors declare that they have no competing interests.

References

1. Halsted WS: I. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 46: 1-19, 1907.
2. Madden JL: Modified radical mastectomy. Surg Gynecol Obstet 121: 1221-1230, 1965.
3. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, et al: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 336: 2087-2106, 1995.
4. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL and Cronin WM: Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333: 1456-1461, 1995.
5. Voogd AC, Nielsen M, Peterse JL, Blickert-Toft M, Bartelink H, Overgaard M, van Tienhoven G, Andersen KW, Sylvester RJ and van Dongen JA: Danish Breast Cancer Cooperative Group. Breast Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer: Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: Pooled results of two large European randomized trials. J Clin Oncol 19: 1688-1697, 2001.
6. Toth BA and Lappert P: Modified skin incisions for mastectomy. The need for plastic surgical input in preoperative planning. Plast Reconstr Surg 87: 1048-1053, 1991.
7. Lanitis S, Tekkis PP, Sgourakis G, Dimopoulos N, Al Mufti R and Hadjiminas DJ: Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer: A meta-analysis of observational studies. Ann Surg 251: 632-639, 2010.
8. Yi M, Kronowitz SJ, Mirc-Bernstam F, Feig BW, Symmans WF, Lucci A, Ross MI, Babiera GV, Kuerer HM and Hunt KK: Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. Cancer 117: 916-924, 2011.
9. Petit JY, Veronesi U, Orecchia R, Rey P, Didier F, Giraldo A, Luini A, De Lorenzi F, Rietjens M, Garusti C, et al: The nipple-sparing mastectomy: Early results of a feasibility study of a new application of perioperative radiotherapy (ELIOT) in the treatment of breast cancer when mastectomy is indicated. Tumori 89: 288-291, 2003.
10. Hinton CP, Doyle PJ, Blamey RW, Davies CJ, Holliday HW and Elston CW: Subcutaneous mastectomy for primary operable breast cancer. Br J Surg 71: 469-472, 1984.
11. Cense HA, Rutgers EJ, Lopes Cardozo M and Van Lanschot JJ: Nipple-sparing mastectomy in breast cancer: A viable option? Eur J Surg Oncol 27: 521-526, 2001.
12. Simmons RM, Brennan M, Christos P, King V and Osborne M: Analysis of nipple/areolar involvement with mastectomy: Can the areola be preserved? Ann Surg Oncol 9: 165-168, 2002.
13. Laronga C, Kemp B, Johnston D, Robb GL and Singletary SE: The incidence of occult nipple-areola complex involvement in breast cancer patients receiving a skin-sparing mastectomy. Ann Surg Oncol 6: 609-613, 1999.
14. Brachtel EF, Rusby JE, Michaelson JS, Chen LL, Muzikansky A, Smith BL and Koerner FC: Occult nipple involvement in breast cancer: Clinicopathologic findings in 316 consecutive mastectomy specimens. J Clin Oncol 27: 4948-4954, 2009.
15. Gerber B, Krause A, Dieterich M, Kunitz G and Reimer T: The oncological safety of skin sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction: An extended follow-up study. Ann Surg 249: 461-468, 2009.
Effect of breast-conserving long-term outcome in young women with breast cancer: A single-centered experience in Taiwan. Ann Plast Surg 74 (Suppl 2): S127-S131, 2015.

Seki T, Jinno H, Okabayashi K, Murata T, Matsumoto A, Takahashi M, Hayashida T and Kitagawa Y: Comparison of oncological safety between nipple sparing mastectomy and total mastectomy using propensity score matching. Ann R Coll Surg Engl 97: 291-297, 2015.

Headon HL, Kasem A and Mokbel K: The oncological safety of Nipple-sparing mastectomy: A systematic review of the literature with a pooled analysis of 12,358 procedures. Arch Plast Surg 43: 328-338, 2016.

Chung WB, Yi JE, Jin JY, Choi YS, Park SY, Park WC, Song BJ and Youn HJ: Early cardiac function monitoring for detection of subclinical Doxorubicin cardiotoxicity in young adult patients with breast cancer. J Breast Cancer 16: 178-183, 2013.

Anders CK, Hsu DS, Broadwater G, Acharyia CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, et al: Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26: 3324-3330, 2008.

Fredholm H, Magnusson K, Lindstrom LS, Garmo H, Falt SE, Lindman H, Bergh J, Holmberg L, Pontén F, Frissell J and Fredriksson I: Long-term outcome in young women with breast cancer: A population-based study. Breast Cancer Res Treat 160: 131-143, 2016.

Bharat A, AR RL, Gao F and Margenthaler JA: Patient and tumor characteristics associated with increased mortality in young women (< or =40 years) with breast cancer. J Surg Oncol 100: 248-251, 2009.

Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I and Lindman H: Breast cancer in young women: Poor survival despite intensive treatment. PLoS One 4: e6905, 2009.

Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N and Margenthaler JA: Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg 208: 341-347, 2009.

Kroman N, Holtevog H, Wohlfahrt J, Jensen MB, Mouridsen HT, Glentoft-Toft M and Melbye M: Effect of breast-conserving therapy versus radical mastectomy on prognosis of young breast cancer patients: Impact of local treatment on survival. Int J Radiat Oncol Biol Phys 81: e533-e539, 2011.

Amin MB, Edge SB, Greene FL, et al: American Joint Committee on cancer (AJCC). AJCC cancer staging manual. 8th ed. New York, Springer, 2017.

National Comprehensive Cancer Network (NCCN): Clinical practice guidelines in oncology. Breast cancer, version, 2007-2016. https://www.nccn.orgprofessionals/physician_glsdefault.aspx/breast.

Rits IA: Declaration of helsinki. Recommendations guidings doctors in clinical research. World Med J 11: 281, 1964.

Kinoshita S, Nogima K, Takeishi M, Imawari Y, Kyoda S, Hirano A, Akiba T, Kobayashi S, Takeyama H, Uchida K and Morikawa T: Retrospective comparison of non-skin-sparing mastectomy and skin-sparing mastectomy with immediate breast reconstruction. Int J Surg Oncol 2011: 876520, 2011.

Burdege CY, Yuen J, Hardee M, Gadgil PV, Das C, Henry-Tillman R, Ochoa D, Korourian S and Suzanne Klimberg V: Nipple skin-sparing mastectomy is feasible for advanced disease. Ann Surg Oncol 20: 3294-3302, 2013.

Benediktsson KP and Perbeck L: Survival in breast cancer after nipple-sparing subcutaneous mastectomy and immediate reconstruction with implants: A prospective trial with 13 years median follow-up in 216 patients. Eur J Surg Oncol 34: 143-148, 2008.

Shimo A, Tsugawa K, Tsuchiya S, Yoshie R, Tsuchiya K, Uejima T, Kojima Y, Shimo A, Hayami R, Nishikawa T, et al: Oncologic outcomes and technical considerations of nipple-sparing mastectomies in young breast cancer: Experience of 425 cases from a single institution. Breast Cancer 23: 851-860, 2016.

Orzalesi L, Casella D, Santi C, Cecconi L, Murgo R, Rinaldi S, Regolo L, Amanti C, Roncella M, Serra M, et al: Nipple sparing mastectomy: Surgical and oncological outcomes from a national multicentric registry with 913 patients (1006 cases) over a six year period. Breast 25: 75-81, 2016.

Morrison DH, Rahardja D, King E, Peng Y and Sarode VR: Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer. Br J Cancer 107: 382-387, 2012.

Tang LC, Jin X, Yang HY, He M, Chang H, Shao ZM and Di GH: Luminal B subtype: A key factor for the worse prognosis of young breast cancer patients in China. BMC Cancer 15: 201, 2015.

Lund MJ, Butler EN, Hair BY, Ward KC, Andrews JH, Oprea-Ilies G, Bayakly AR, O'Regan RM, Vertino PM and Eley JW: Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: A population-based study and first report. Cancer 116: 2549-2559, 2010.

Colleoni M, Rotmensch N, Robertson C, Orlando L, Viale G, Renne G, Luini A, Veronesi P, Intra M, Orecchia R, et al: Very young women (<35 years) with operable breast cancer: Features of disease at presentation. Ann Oncol 13: 273-279, 2002.

Petit JY, Veronesi U, Orecchia R, Curigliano G, Rey PC, Botteri E, Rotmensch N, Lohsirivat V, Cassilha Kneubil M and Rietjens M: Risk factors associated with recurrence after nipple-sparing mastectomy for invasive and intraepithelial neoplasia. Ann Oncol 23: 2053-2058, 2012.

Donovan CA, Harit AP, Chung A, Bao J, Giuliano AE and Amersi F: Oncological and surgical outcomes after Nipple-sparing mastectomy: Do incisions matter? Ann Surg Oncol 23: 3226-3231, 2016.

Laporta R, Longo B, Sorotos M, Fachawenzi A, Patti C, Mastrandeli MR, Rubino C and Santanelli di Pompeo F: Breast reconstruction following nipple-sparing mastectomy: Clinical outcomes and risk factors related complications. J Plast Surg Hand Surg 51: 427-435, 2017.

Salgarello M, Visconti G and Barone-Adesi L: Nipple-sparing mastectomy with immediate implant reconstruction: Cosmetic outcomes and technical refinements. Plast Reconstr Surg 126: 1460-1471, 2010.

Yueh JH, Houllihan MJ, Slavin SA, Lee BT, Pories SE and Morris DJ: Nipple-sparing mastectomy: Evaluation of patient satisfaction, aesthetic results, and sensation. Ann Plast Surg 62: 586-590, 2009.

Fobair P, Stewart SL, Chang S, D’Onofrio C, Banks PJ and Suzanne Klimberg V: Nipple sparing mastectomy in young women with breast cancer. Psycho Oncol 15: 579-594, 2006.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.